Kinito

Itopride Hydrochloride, the active ingredient in Kinito, is a gastroprokinetic presented as an oral tablet for oral use. It treats functional dyspepsia and related gastric motility disorders in adults.

GNH USA supplies Kinito as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kinito, a gastroprokinetic, is used to improve gastrointestinal motility in several functional disorders.

- Functional dyspepsia: relieves upper abdominal discomfort, early satiety and bloating. - Gastric motility disorders: enhances gastric emptying and reduces stasis. - Gastroesophageal reflux disease (GERD): supports lower esophageal sphincter function and reduces reflux episodes.

Kinito may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dry mouth: reduced salivary flow. - Diarrhea: increased bowel frequency. - Nausea: mild stomach upset. - Headache: occasional tension-type pain. - Dizziness: brief light‑headed sensations. - Abdominal pain: mild cramping.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heartbeat. - Hepatic dysfunction: abnormal liver enzyme levels. - Extrapyramidal symptoms: rare movement disorders. - Blood dyscrasias: unexplained bruising or anemia. - Persistent vomiting: may indicate intolerance.

Before prescribing Kinito, consider the following safety measures.

- Allergy assessment: avoid use in patients with known hypersensitivity to itopride or excipients. - Hepatic function: use cautiously in moderate liver impairment; monitor liver enzymes. - Renal function: dose adjustment may be needed in severe renal insufficiency. - Concomitant medications: review for drugs that affect dopamine pathways or cholinergic activity. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Kinito can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may diminish prokinetic effect. - Strong CYP3A4 inhibitors: could increase plasma levels of itopride. - QT‑prolonging drugs: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Dopamine antagonists (e.g., metoclopramide): potential additive dopaminergic blockade. - Antidepressants affecting serotonin: monitor for gastrointestinal side effects. - Diuretics: watch for electrolyte disturbances that may exacerbate dizziness.